Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma

International Journal of Hematology

Volumn 84, Issue 2, 2006, Pages 174-181

  Han, Li Na ^a,b   Zhou, Jin ^a   Hirose, Takayuki ^b   Imai, Yosuke ^b   Ishiguro, Takuro ^b   Chou, Takaaki ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

Aggressive relapsed NHL; ASCT; High dose chemotherapy; LEED; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; HYPONATREMIA; INFECTION; LUNG DISEASE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; SURVIVAL RATE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 33748412735     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06023     Document Type: Article

References (37)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
2. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-1295.
3. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290-1297.
4. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472-2479.
5. Fanin R, Sperotto A, Ruiz De Elvira C, et al. A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of autologous stem cell transplantation in first remission on outcome. Haematologica. 2000;85:943-951.
6. Ogura M, Kagami Y, Taji H, et al. Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol. 2003;77:503-511.
7. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
8. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520-535.
9. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:4561-4566.
10. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864-869.
11. Flohr T, Hess G, Kolbe K, et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant. 2002;29:769-775.
12. Joyce RM, Regan M, Ottaway J, et al. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Ann Oncol. 2003;14(suppl 1):i21-i27.
13. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:2240-2247.
14. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
16. Makino S, Harada M, Akashi K, et al. A simplified method for cryopreservation of peripheral blood stem cells at -80°C without rate-controlled freezing. Bone Marrow Transplant. 1991;8:239-244.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255-1262.
19. Kleiner S, Kirsch A, Schwaner I, et al. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Bone Marrow Transplant. 1997;20:953-959.
20. Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma. 2003;44:1151-1158.
21. van Imhoff GW, van der Holt B, Mackenzie MA, et al. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-Hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol. 2005;23:3793-3801.
22. Waheed F, Kancherla R, Seiter K, et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma. 2004;45:2253-2259.
23. Economopoulos T, Fountzilas G, Pavlidis N, et al. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J. 2003;4:110-115.
24. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005;46:1569-1573.
25. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684-3688.
26. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103:777-783.
27. Hirose A, Yamane T, Nakajima Y, et al. Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma [in Japanese]. Gan To Kagaku Ryoho. 2005;32:2059-2064.
28. Hess G, Flohr T, Derigs HG. Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL. Ann Hematol. 2002;81(suppl 2):S54-S55.
29. Benekli M, Hahn T, Shafi F, et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant. 2003;32:139-143.
30. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
31. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102:749-755.
32. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immune-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol. 2002;116:229-235.
33. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165-2170.
34. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153-2164.
35. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol. 1997;15:1131-1137.
36. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol: a Groupe d'Etude des Lymphomas de l'Adulte study. J Clin Oncol. 2000;18:3025-3030.
37. Usui N, Yano S, Asai O, et al. Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas. Clin Lymphoma. 2005;6:31-36.